Boryung Pharmaceutical Develops Multiple Myeloma Treatment as COVID-19 Therapy

[Asia Economy Reporter Cho Hyun-ui] Boryung Pharmaceutical announced on the 2nd that it will develop 'Apladin,' a multiple myeloma treatment introduced from a Spanish pharmaceutical company, as a treatment for coronavirus disease 2019 (COVID-19).

According to research conducted by a domestic research institute commissioned by Boryung Pharmaceutical, Apladin showed superior antiviral effects compared to the COVID-19 treatment 'Remdesivir' in cell experiments conducted on monkey kidney cells and human lung cells, respectively.

Apladin is a multiple myeloma treatment for which Boryung Pharmaceutical signed an exclusive domestic sales contract with Spain's Pharmamar in 2016. It is currently marketed as a multiple myeloma treatment in Australia. It has been approved for Phase 3 clinical trials for multiple myeloma in the United States and Europe, and its safety has been confirmed as it has been administered to hundreds of patients.

Pharmamar has been conducting clinical trials in Spain since April to develop Apladin as a COVID-19 treatment. Boryung Pharmaceutical also aims to start domestic clinical trials within the third quarter of this year.

Lee Sam-su, president of Boryung Pharmaceutical, said, "We will develop Apladin into a safe and effective COVID-19 treatment through in-depth research."

This content was produced with the assistance of AI translation services.